Real-life efficacy and drug continuation of secukinumab in treating moderate to severe plaque psoriasis in Aegean region of Turkey: a multicenter retrospective study and systematic review of the literature
Nida Kaçar,1 Didem Didar Balcı,2 Sinan Doğan,3 Meltem Türkmen,3 Melis Gönülal,2 Gökhan Çınar1
1 Pamukkale University, Faculty of Medicine, Department of Dermatology, Denizli, Turkey
2 Tepecik Training and Research Hospital, Department of Dermatology, Izmir, Turkey
3 Bozyaka Training and Research Hospital, Department of Dermatology, Izmir, Turkey
Abstract
Background: Secukinumab was demonstrated to be efficient in the treatment of moderate to severe plaque psoriasis in the phase studies. Real-life treatment experiences obtained from patients that do not meet the inclusion criteria of phase studies can provide valuable information on efficacy and safety results. Results may also differ in different ethnic populations.
Objective: To investigate short and long-term efficacy and drug continuation of secukinumab in Turkish population.
Methods: The study conducted in three tertiary care psoriasis centers. Patients’ demographic characteristics and week 0 / 4th week / 12th week / 1st year PASI values were analyzed. For systematic review of the literature a PubMed search using the keywords “secukinumab and real and psoriasis” from inception to April 2021 was performed.
Results: Mean PASI scores improved the compared to baseline at all assessment weeks (p = 0.000). In multivariate model, we found that bioexperience have negative influence on the PASI90 response at week 4. Univariate analysis showed significant relationship only between PASI90 response rate and gender at week 12 and year 1. Approximately 85% of patients remained on secukinumab treatment at the end of one year.
Conclusions: Secukinumab seems to be an effective treatment option for plaque psoriasis. According to our knowledge, this is the first study concerning about long-term efficacy and drug continuation of secukinumab from Turkey.
Key words: real, real-life, real-world, psoriasis, treatment, secukinumab, biologics, anti-IL17